Search Results

No Results

    Recently Viewed

      Listening...

      Sorry, I don't understand. Please try again
      1. Home/
      2. Oncology/
      3. Johnson & Johnson’s Oncology Care Index uncovers barriers and opportunities to improve cancer care in the U.S.
      Web
      Oncology

      Johnson & Johnson’s Oncology Care Index uncovers barriers and opportunities to improve cancer care in the U.S.

      What 500 oncology professionals say about the current state of cancer care

      Written by Johnson & Johnson
      May 4, 2025
      May 4, 2025
      A man and woman smiling

      J&J Microsite Infographic_V1_redesign (1).webp

      Download a PDF version of the infographic here.

      From the unprecedented pace of new treatment developments, to AI-powered tools and complex treatment guidelines, oncology professionals are finding it increasingly challenging to keep up with changes in the field.

      At Johnson & Johnson, we’re working to get in front of cancer, driving the next wave of innovation in cancer care. As part of this work, we are committed to working with the oncology healthcare community to bridge gaps, remove barriers, and support oncology care professionals as they work to deliver the latest advancements to every patient, no matter where they receive care.

      For media inquiries and additional insights, view our press release

      Learn more
      TB researchers in a lab in China

      Learn more about J&J’s therapies in multiple myeloma, bladder cancer, lung cancer, and prostate cancer.

      Research Methodology

      • The research was conducted online in the United States by The Harris Poll on behalf of Johnson & Johnson among 500 adults age 18+ who are duly licensed and either hematologists/oncologists, urologists, APPs in hematology/oncology, or APPs in urology. Oncologists and APP oncologists must treat at least 1 patient with blood and 1 patient with solid-state tumor cancer, while urologists and APP urologists must treat at least 1 patient with solid-state tumor cancer. The survey was conducted November 21 – December 13, 2024.
      • Data for MDs are weighted where necessary by hematologists/oncologists and urologists for age and gender to bring them in line with their actual proportions in their specialty populations, with APP hem/oncs and APP uros later combined into their respective specialty total. Raw data for APPs are not weighted and therefore only representative of the individual APPs surveyed.
      • Respondents for this survey were selected among those who have agreed to participate in our surveys. The sampling precision of Harris online polls is measured by using a Bayesian credible interval. For this study, the sample data are accurate to within ± 7.4 percentage points using a 95% confidence level. This credible interval will be wider among subsets of the surveyed population of interest.
      • All sample surveys and polls, whether or not they use probability sampling, are subject to other multiple sources of error which are most often not possible to quantify or estimate, including, but not limited to coverage error, error associated with nonresponse, error associated with question wording and response options, and post-survey weighting and adjustments.